Role of thiazolidinediones in the management of type 2 diabetes: Focus on ethnic minority populations

Ethnicity and Disease

Volumn 16, Issue 1, 2006, Pages 51-57

  Umpierrez, Guillermo ^a   Dagogo Jack, Samuel ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Diabetes; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BENZOIC ACID DERIVATIVE; BIGUANIDE; CHLORPROPAMIDE; DEXTRO PHENYLALANINE; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE; GLIPIZIDE; GLIPIZIDE PLUS METFORMIN; HEMOGLOBIN A1C; INSULIN; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA; TOLBUTAMIDE;

CARDIOVASCULAR RISK; CAUCASIAN; COMBINATION CHEMOTHERAPY; DRUG EFFECT; ETHNIC GROUP; FIBRINOLYSIS; FLUID RETENTION; GLUCONEOGENESIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PREVALENCE; REVIEW; RISK REDUCTION; SIDE EFFECT; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; ARTICLE; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; PATHOPHYSIOLOGY; RACE; RISK FACTOR;

BLOOD GLUCOSE; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 33744998128     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414-1431.
2. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21(4):518-524.
3. National Center for Chronic Disease Prevention and Health Promotion. National Diabetes Surveillance System. Available at: www.cdc.gov. Accessed on: 2/26/2005.
4. Carter JS, Pugh JA, Monterrosa A. Non-insulin-dependent diabetes mellitus in minorities in the United States. Ann Intern Med. 1996;125(3):221-232.
5. Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the U.S.: 1990-1998. Diabetes Care. 2000;23(9):1278-1283.
6. Fujimoto WY. Diabetes in Asian and Pacific Islander Americans. In: Diabetes in America. 2nd ed, Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH, eds. Bethesda, Md: National Institutes of Health, 1995;661-668.
7. Lindsay RS, Bennett PH. Type 2 diabetes, the thrifty phenotype - an overview. Br Med Bull. 2001;60:21-32.
8. Wareham NJ, Franks PW, Harding AH. Establishing the role of gene-environment interactions in the etiology of type 2 diabetes. Endocrinol Metab Clin North Am. 2002;31(3):553-566.
9. Zimmet P, Thomas CR. Genotype, obesity, and cardiovascular disease-has technical and social advancement outstripped evolution? J Intern Med. 2003;254(2):114-125.
10. Stern MP, Gonzalez C, Mitchell BD, Villalpando E, Haffner SM, Hazuda HP. Genetic and environmental determinants of type II diabetes in Mexico City and San Antonio. Diabetes. 1992;41(4):484-492.
11. Karter AJ, Mayer-Davis EJ, Selby JV, et al. Insulin sensitivity and abdominal obesity in Aftican-American, Hispanic, and non-Hispanic White men and women. The Insulin Resistance and Atherosclerosis Study. Diabetes. 1996;45(11):1547-1555.
12. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288(14):1723-1727.
13. Kumanyika SK. Minisymposium on obesity: overview and some strategic considerations. Annu Rev Public Health. 2001;22:293-308.
14. Haffner SM, Stern MP, Hazuda HP, Rosenthal M, Knapp JA. The role of behavioral variables and fat patterning in explaining ethnic differences in serum lipids and lipoproteins. Am J Epidemiol. 1986;123(5):830-839.
15. Stevens J, Keil JE, Rust PF, Tyroler HA, Davis CE, Gazes PC. Body mass index and body girths as predictors of mortality in Black and White women. Arch Intern Med. 1992;152(6):1257-1262.
16. Dowling HJ, Pi-Sunyer FX. Race-dependent health risks of upper body obesity. Diabetes. 1993;42(4):537-543.
17. Kissebah AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab. 1982;54(2):254-260.
18. Peiris AN, Sothmann MS, Hoffmann RG, et al. Adiposity, fat distribution, and cardiovascular risk. Ann Intern Med. 1989;110(11):867-872.
19. Greaves KA, Puhl J, Baranowski T, Gruben D, Seale D. Ethnic differences in anthropometric characteristics of young children and their parents. Hum Biol. 1989;61(3):459-477.
20. Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE. Body composition, visceral fat, leptin, and insulin resistance in Asian-Indian men. J Clin Endocrinol Metab. 1999;84(1):137-144.
21. Raji A, Seely EW, Arky RA, Simonson DC. Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. J Clin Endocrinol Metab. 2001;86(11):5366-5371.
22. Crespo CJ, Smit E, Andersen RE, Carter-Pokras O, Ainsworth BE. Race/ethnicity, social class and their relation to physical inactivity during leisure time: results from the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Prev Med. 2000;18(1):46-53.
23. Lands WE, Hamazaki T, Yamazaki K, et al. Changing dietary patterns. Am J Clin Nutr. 1990;51(6):991-993.
24. Dixon LB, Sundquist J, Winkleby M. Differences in energy, nutrient, and food intakes in a US sample of Mexican-American women and men: findings from the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol. 2000;152(6):548-557.
25. Harris MI, Klein R, Cowie CC, Rowland M, Byrd-Holt DD. Is the risk of diabetic retinopathy greater in non-Hispanic Blacks and Mexican Americans than in non-Hispanic Whites with type 2 diabetes? A US population study. Diabetes Care. 1998;21(8):1230-1235.
26. Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med. 1989;321(16):1074-1079.
27. Young BA, Maynard C, Reiber G, Boyko EJ. Effects of ethnicity and nephropathy on lower-extremity amputation risk among diabetic veterans. Diabetes Care. 2003;26(2):495-501.
28. Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV. Ethnic disparities in diabetic complications in an insured population. JAMA. 2002;287(19):2519-2527.
29. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971-1993. Diabetes Care. 1998;21(7):1138-1145.
30. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104(6):787-794.
31. Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest. 2000;106(3):329-333.
32. Kahn SE. Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab. 2001;86(9):4047-4058.
33. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607.
34. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol. 1999;83(9B):25F-29F.
35. Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
36. Chiu KC, Cohan P, Lee NP, Chuang LM. Insulin sensitivity differs among ethnic groups with a compensatory response in beta-cell function. Diabetes Care. 2000;23(9):1353-1358.
37. Haffner SM, Howard G, Mayer E, et al. Insulin sensitivity and acute insulin response in African Americans, non-Hispanic Whites, and Hispanics with NIDDM: the Insulin Resistance Atherosclerosis Study. Diabetes. 1997;46(3):63-69.
38. Porte D Jr. Banting lecture 1990. Beta-cells in type II diabetes mellitus. Diabetes. 1991;40(2):166-180.
39. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865.
40. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
41. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
42. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342(6):381-9, Erratum in: N Engl J Med. 2000;342(18):1376.
43. Stratton IM, Adler AI, Neil HA, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.
44. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421-431.
45. Yoshioka N, Kuzuya T, Matsuda A, Iwamoto Y. Effects of dietary treatment on serum insulin and proinsulin response in newly diagnosed NIDDM. Diabetes. 1989;38(2):262-266.
46. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005-2012.
47. Ruderman N, Apelian AZ, Schneider SH. Exercise in therapy and prevention of type II diabetes. Implications for Blacks. Diabetes Care. 1990;13(11):1163-1168.
48. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2005;28(suppl 1):S4-S36.
49. Luna B, Feinglos MN. Oral agents in the management of type 2 diabetes mellitus. Am Fam Physician. 2001;63(9):1747-1756.
50. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287(3):360-372.
51. Dagogo-Jack S, Santiago JV. Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions. Arch Intern Med. 1997;157(16):1802-1817.
52. Wagman AS, Nuss JM. Current therapies and emerging targets for the treatment of diabetes. Curr Pharm Des. 2001;7(6):417-450.
53. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med. 1994;121(12):928-935.
54. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333(9):541-549.
55. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998;338(13):867-872.
56. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9):574-579.
57. Davis TM, Cull CA, Holman RR. Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: UK Prospective Diabetes Study (UKPDS 55). Diabetes Care. 2001;24(7):1167-1174.
58. Agrawal L, Emanuele NV, Abraira C, et al. Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in type 2 diabetes mellitus (VA CSDM). Diabetes Care. 1998;21(4):510-515.
59. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45(12):1661-1669.
60. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998;47(4):507-514.
61. Hsueh WA, Jackson S, Law RE. Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care. 2001;24(2):392-397.
62. Haffner SM, D'Agostino R, Saad MF, et al. Increased insulin resistance and insulin secretion in non-diabetic African Americans and Hispanics compared with non-Hispanic Whites. The Insulin Resistance Atherosclerosis Study. Diabetes. 1996;45(6):742-748.
63. Wagenknecht LE, Langefeld CD, Scherzinger AL, et al. Insulin sensitivity, insulin secretion, and abdominal fat: The Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes. 2003;52(10):2490-2496.
64. Osei K, Miller E, Everit DE, Ilgenfritz J, Porter LE, Freed MI. Rosiglitazone is effective and well tolerated as monotherapy in African Americans with type 2 diabetes. Diabetes. 2001;50(suppl 2):512A.
65. Gomez-Perez FJ, Fanghanel-Salmon G, Antonio Barbosa J, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev. 2002;18(2):127-134.
66. Xixing Z, Channgyu PG, Hongli S, et al. Rosiglitazone has a favorable safety profile in Chinese type 2 diabetes with previous exposure to hepatitis B or C infection. Diabetes. 2001;50(suppl 2):1863A.
67. Porter LE, Freed MI, Jones NP. Rosiglitazone improves β-cell function as measured by proinsulin/insulin ratio in patients with type 2 diabetes. Diabetes. 2000;49(suppl 1):A122.
68. Finegood DT, McArthur MD, Kojwang D, et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes. 2001;50(5):1021-1029.
69. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001;86(1):280-288.
70. Matthews DR, Bakst AW, Weston WM. Rosiglitazone decreases insulin resistance and improves B-cell function in patients with type 2 diabetes. Diabetologia. 1999;42:A228.
71. Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycemic control in type 2 diabetic patients. Diabet Med. 2000;17(1):40-47.
72. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care. 2001;24(2):308-315.
73. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24(7):1226-1232.
74. Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab. 1999;1(3):165-172.
75. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care. 2000;23(11):1605-1611.
76. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106-1118.
77. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab. 2004;89(12):6068-6076.
78. Groop L, Widen E, Franssila-Kallunki A, et al. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1989;32(8):599-605.
79. Bell DS. Beneficial effects resulting from thiazolidinediones for treatment of type 2 diabetes mellitus. Postgrad Med. 2003;special issue:35-44.
80. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care. 2002;25(5):815-821.
81. Jun JK, Gong WC, Mathur R. Effects of pioglitazone on diabetes-related outcomes in Hispanic patients. Am J Health Syst Pharm. 2003;60(5):469-473.
82. King AB, Armstrong DU, Chinnapongse S. Comparison of glycemic and lipid response to pioglitazone treatment in Mexican Americans and non-Hispanic Caucasians with type 2 diabetes. Diabetes Care. 2003;26(1):245-246.
83. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683-689.
84. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes. 1992;41(6):715-722.
85. Trevisan M, Liu J, Bahsas FB, Menotti A. Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. Am J Epidemiol. 1998;148(10):958-966.
86. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356-359.
87. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 1997;46(1):3-10.
88. Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes. 1999;107(2):119-125.
89. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care. 2003;26(1):172-178.
90. Nordt TK, Peter K, Bode C, Sobel BE. Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells. J Clin Endocrinol Metab. 2000;85(4):1563-1568.
91. Law RE, Goetze S, Xi XP, et al. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation. 2000;101(11):1311-1318.
92. Ginsberg H, Plutzky J, Sobel BE. A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering. J Cardiovasc Risk. 1999;6(5):337-346.
93. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination thetapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283(13):1695-1702.
94. Erle G, Lovise S, Stocchiero C, et al. A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients. Acta Diabetol. 1999;36(1-2):61-65.
95. Wyne KL, Drexler AJ, Miller JL, Bell DS, Braunstein S, Nuckolls JG. Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones. Postgrad Med. 2003;special issue:63-72.
96. Garber AJ, Donovan DS Jr, Dandona P, Bruce S, Park JS. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab. 2003;88(8):3598-3604.
97. Marre M, Howlett H, Lehert P, Allavoine T. Improved glycemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in type 2 diabetic patients inadequately controlled on metformin. Diabet Med. 2002;19(8):673-680.